Nov 1, 2011
By:
Rich Whitworth
The middle word in our magazine's title is technology, so I cannot fail to join the increasing numbers of people in all fields of business commenting on the passing of Steve Jobs.
|
Oct 26, 2011
By:
Rich Whitworth
Another very busy day at CPhI Worldwide and co-located events with good meetings in every corner for all exhibitors.
|
Oct 26, 2011
By:
Rich Whitworth
PTE Editor, Rich Whitworth, gives an update on Day 1 of CPhI, including the Innovation Awards.
|
Oct 24, 2011
By:
Rich Whitworth
PTE Editor, Rich Whitworth, reports on the CPhI pre-show conference.
|
Oct 20, 2011
By:
Rich Whitworth
Roche signed a definitive agreement to acquire Anadys Pharmaceuticals. The two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of $3.70 per share in an all-cash transaction.
|
Oct 13, 2011
By:
Rich Whitworth
After announcing the official appointment of Guido Rasi as new executive director, the EMA management board also endorsed the implementation plan for the agency's 'Road Map to 2015.'
|
Oct 6, 2011
By:
Rich Whitworth
EMA released two concept papers for consultation that address the need to revise existing guidelines on biosimilar medicines and influenza vaccines.
|
Oct 1, 2011
By:
Rich Whitworth
As editor of Pharmaceutical Technology Europe, I often have the opportunity to visit the sites of a wide variety of companies within the industry. Though differing vastly in the technologies and staff they employ, they all share one thing in common for me: the "you learn something new every day!" factor.
|
Sep 22, 2011
By:
Rich Whitworth
Pfizer plans to invest EUR 145 million ($200 million) in its Grange Castle biotech-manufacturing site. Meanwhile, completion of the merger between Alkermes, Inc. and Elan Drug Technologies was announced in a press release on Sept. 16, 2011, following the approval by Alkermes, Inc. shareholders on Sept. 8, 2011.
|
|
